Emerging data suggest Retatrutide , a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , may offer a promising development for obesity management . Early clinical tests https://getretatrutideaustralia.com/blog/retatrutide-vs-tirzepatide-semaglutide